CXCR4 and neoplasm: As shown in Figure 4B, top panel, CD8 depletion in MOVCAR 5009 tumor-bearing WT mice abrogated OV-CXCR4-A treatment-mediated control of tumor growth (p = 0.03), which was more pronounced compared with depletion of CD4+ T cells.